Product
Piperacillin/tazobactam
5 clinical trials
12 indications
Indication
Enterobacteriaceae InfectionsIndication
BacteremiaIndication
Late-Onset Neonatal SepsisIndication
Perforated AppendicitisIndication
Chronic Obstructive Pulmonary DiseaseIndication
Respiratory Tract InfectionsIndication
Pseudomonas aeruginosaIndication
BronchiectasisIndication
AsthmaIndication
Hematologic NeoplasmsIndication
NeutropeniaClinical trial
Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in the Treatment of Late-onset Sepsis in Preterm Neonates: a Multicentre, Randomised, Open-label, Non-inferiority Study.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Assessing the Longitudinal Outcomes of Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA): a Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter, Randomized, Controlled, Open-label Trial.Status: Terminated, Estimated PCD: 2023-03-01
Clinical trial
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority StudyStatus: Recruiting, Estimated PCD: 2025-07-31